Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.

Xi Wang,Cheng-Sheng Zhang,Xu-Yuan Dong,Yuan Hu,Bao-Jun Duan,Jun Bai,Yin-Ying Wu,Lin Fan,Xin-Hua Liao,Ye Kang,Peng Zhang,Meng-Yang Li,Jiao Xu,Zhi-Jun Mao,Hui-Tong Liu,Xiao-Long Zhang,Li-Fei Tian,En-Xiao Li

World journal of gastrointestinal oncology（2022）

Cited 6|Views31
No score
Abstract
CLDN18.2 expression is frequently increased in PDAC patients. Thus, it may act as a potential therapeutic target for zolbetuximab in PDAC.
More
Translated text
Key words
Claudin 18.2, Immunohistochemistry,Diagnosis,Pancreatic ductal adenocarcinoma,Prognosis,Therapeutic target
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined